Advancing a multi-asset pipeline of high-impact therapeutic solutions

Our flagship product candidates, BackBeat CNT and Virtue SAB, exemplify key criteria that characterize innovations optimized for strategic partnerships:

• Target mature therapeutic device markets with significant unmet needs
• Provide high impact procedure-based solutions with rapid adoption potential
• Offer strategic and financial benefits to a commercial partner and Orchestra BioMed

*Plan to leverage existing coronary in-stent restenosis (ISR) data to support potential Pivotal Study; Virtue SAB has received Breakthrough Device Designation for: ¹The balloon dilatation of the stenotic portion (up to 26 mm length) of a stented coronary artery that is 2.25 to 4.0 mm in diameter, for the purpose of improving lumen diameter; ²The balloon dilation of the de novo stenotic portion (up to 26mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for the purpose of improving lumen diameter; ³The balloon dilatation of the stenotic portion (up to 18 mm length) of an infrapopliteal artery (P-3 segment or distal, below the knee, with reference vessel diameter (RVD) 2.25 - 4.0 mm), for the purpose of improving lumen diameter.